Familial hyperaldosteronism

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 10, 2000, Pages 1149-1155

  Torpy, D J ^a   Stratakis, C A ^b   Chrousos, G P ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Adrenal tumour; Aldosterone; Genetics; Hyperaldosteronism; Hypertension

Indexed keywords

ALDOSTERONE SYNTHASE; STEROID 11BETA MONOOXYGENASE;

CLASSIFICATION; GENETICS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; REVIEW;

ALDOSTERONE SYNTHASE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; STEROID 11-BETA-HYDROXYLASE;

EID: 0034297062     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000001000004     Document Type: Article

References (55)

1. Mornet E, Dupont J, Vitek A & White PC (1989). Characterisation of the two genes encoding human steroid 11ß-hydroxylase (P-450 (11)ß). Journal of Biological Chemistry, 264: 20961-20967.
2. Curnow KM, Tusie-Luna MT, Pascoe L, Natarajan R, Gu JL, Nadler JL & White PC (1991). The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Molecular Endocrinology, 5: 1513-1522.
3. Taymans SE, Pack S, Pak E, Torpy DJ, Zhuang Z & Stratakis CA (1998). Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. Journal of Clinical Endocrinology and Metabolism, 83: 1033-1036.
4. McKenna TJ, Island DP, Nicholson WE & Liddle GW (1978). The effect of potassium on early and late steps in aldosterone biosynthesis in cells of the zona glomerulosa. Endocrinology, 103: 1411-1416.
5. Clyne CD, Zhang Y, Slutsker L, Mathis JM, White PC & Rainey WE (1997). Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Molecular Endocrinology, 11: 638-649.
6. Brown JJ, Davies DL & Lever AF (1964). Variations in plasma renin concentration in several physiological and pathological states. Journal of the Canadian Medical Association, 90: 201-206.
7. Gaillard RC, Riondel AM, Farrod-Coune CA, Valloton MB & Muller AF (1983). Aldosterone escape to chronic ACTH administration in man. Acta Endocrinologica, 103: 116-124.
8. Blair-West JR, Coughlin JP, Denton DA, Fei DT, Hardy KJ, Scoggins BA & Wright RD (1980). A dose response comparison of the actions of angiotensm II and III in sheep. Journal of Endocrinology, 87: 409-417.
9. Carey RM (1982). Acute dopaminergic inhibition of aldosterone secretion is independent of angiotensin II and adrenocorticotropin. Journal of Clinical Endocrinology and Metabolism, 54: 463-469.
10. Sheppard KE & FunderJW (1987). Equivalent affinity of aldosterone and corticosterone for type I receptors in kidney and hippocampus: direct binding studies. Journal of Steroid Biochemistry, 28: 737-742.
11. Sheppard KE & Funder JW (1987). Type I receptors in parotid, colon, and pituitary are aldosterone selective in vivo. American Journal of Physiology, 253: E467-471.
12. Funder JW (1995). Apparent mineralocorticoid excess. Endocrinology and Metabolism Clinics of North America. 24: 613-621.
13. Ishimori K, Takeda A, Okumora S, Murai T, Inouye H & Yasuda K (1994). Increased insulin sensitivity in patients with aldosterone produc ng-adenoma. Clinical Endocrinology, 41: 433-438.
14. Shimamoto K, Shiiki M, Ise T, Miyazaki Y, Higashiura K, Fukuoka M, Hirata A, Masuda A, Nakagawa M & Iimura O (1994). Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? Journal of Human Hypertension, 8: 755-759.
15. Torpy DJ, Bornstein SR, Taylor W, Tauchnitz R & Gordon RD (1999). Leptin levels are suppressed in primary aldosteron sm. Hormone and Metabolic Research, 31: 533-536.
16. Conn JW (1965). Hypertension, the potassium ion and impaired glucose tolerance. New England Journal of Medicine, 273: 1135-1143
17. Campbell SE, Diaz-Arias AA & Weber KT (1992), Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Pressure, 1: 149-156
18. Sun Y, Ramires FJ & Weber KT (1997). Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovascular Research, 35: 138-147.
19. Robert V, Heymes C, Silvestre JS, Sabri A. Swynghedauw B & Delcayre C (1999). Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension, 33: 981-986.
20. Conn JW (1955). Primary aldosteron sm, a new clinical syndrome. Journal of Laboratory and Clinical Medicine, 45: 3-17.
21. Conn JW, Knopf RF & Nesbit RM (1964). Clinical characteristics of primary aldosteronism from an analysis of 145 cases. American Journal of Surgery, 107: 159-172.
22. Kaplan NM (1992). Endocrine hypertension. In: Wilson JD & Foster DW (Editors), Williams Textbook of Endocrinology, 8th edn. WB Saunders, Philadelphia, 707-731
23. Streeten DHP, Tomycz N & Anderson Jr GH (1979), Reliability of screening methods for the diagnosis of primary aldosteronism. American Journal of Medicine, 67: 403-413.
24. Gordon RD, Stowasse' M, Tunny TJ, Klemm SA & Rutherford JC (1994). High incidence of primary hyperaldosteronism in 199 patients referred with hypertension. Clinical and Experimental Pharmacology and Physiology, 21: 315-318
25. Gordon RD (1995). Primary aldosteronism. Journal of Endocrinological Investigation, 18: 495-511.
26. Weisnagel SJ, Gagner M, Breton G, Pomp A, Pharand D & Lacroix A (1996). Laparoscopic adrenalectomy. Endocrinologist, 6: 169-178.
27. Litchfield WR & Dluhy RG (1995). Primary aldosteronism. Endocrinology and Metabolism Clinics of North America, 24 593-612.
28. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H & Izumiyama T (1981). A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Archives of internal Medicine, 141: 1589-1593.
29. McKenna TJ, Sequeira SJ, Heffeman A, Chambers J & Cunningham S (1991). Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. Journal of Clinical Endocrinology and Metabolism, 73 952-957.
30. Ignatowska-Switalska H, Chodakowska J, Januszewicz W, Feltynowski T, Adamczyk M & Lewandowski J (1997). Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism. Journal of Human Hypertension, 11: 373-378.
31. Melby JC (1991). Diagnosis of hyperaldosteronism. Endocrinology and Metabolism Clinics of North America, 20: 247-255.
32. Bravo EL, Turazi RC & Dustan HP (1983). The changing clinical spectrum of primary aldosteronism. American Journal of Medicine, 74: 641-651.
33. Hambling C, Jung RT, Gunn A, Browning MC & Bartlett WA (1992). Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clinical Endocrinology, 36 499-503
34. Iwaoka T, Umeda T, Naomi S, Inoue J, Sasaki M, Yamauchi J & Sato T (1993). The usefulness of the captopril test as a simultaneous screening for primary aldosteronism and renovascular hypertension. American Journal of Hypertension, 6: 899-906.
35. Young Jr WF & Klee GG (1988). Primary aldosteronism: diagnostic evaluation. Endocrinology and Metabolism Clinics of North America, 17: 367-395.
36. Ulick S, Blumenfield JD. Atlas SA, Wang JZ & Vaughan Jr ED (1993). The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism, 76: 873-878.
37. Doppman JL & Gill Jr JR (1996). Hyperaldosteronism: sampling the adrenal veins. Radiology, 198: 309-312.
38. Young Jr WF (1997). Primary hyperaldosteronism: update on diagnosis and treatment. Endocrinologist, 7: 213-221
39. Biglieri EG (1997). Primary aldosteronism. Current Therapy in Endocrinology and Metabolism, 6: 170-172
40. Beckers A, Abs R & Willems PJ (1992). Aldesterone secreting adenoma as part of multiple endocrine neoplasia type 1 (MEN I): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN locus. Journal of Clinical Endocrinology and Metabolism, 75: 564-570.
41. Sutherland DJA, Ruse JC & Laidlaw JC (1966). Hypertension increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Journal of the Canadian Medical Association, 95: 1109-1119
42. Pascoe L, Jeunemaitre X, Lebrethon MC, Curnow KM, Gomez-Sanchez CE, Gasc JM, Saez JM & Corvol P (1995). Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. Journal of Clinical Investigation, 96: 2236-2246.
43. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S & Lalouel JM (1992). A chimaeric 11ß-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteron sm and human hypertension. Nature, 355: 262-265.
44. Ulick S & Chu MD (1982). Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. Clinical and Experimental Hypertension, A4: 1771-1777.
45. Jamieson A, Slutsker L, Inglis GC, Fraser R, White PC & Connel JM (1995). Glucocorticoid suppressible hyperaldosteronism: effects of cross-over site and parental origin of chimaeric gene on phenotypic expression. Clinical Science. 88: 563-570.
46. White PC (1997). Abnormalities of aldosterone synthesis ard action in children. Current Opinion in Pediatrics, 9: 424-430.
47. Gates LJ, MacConnachie AA, Lifton RP, Hartes NE & Benjamin N (1996) Variation of phenotype in patients with GRA. Journal of Medical Genetics, 33: 25-28
48. Litchfield WR, New MI, Coolidge C, Lifton RP & Dluhy RG (1997) Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. Journal of Clinical Endocrinology and Metabolism, 82: 3570-3573
49. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP & Dluhy RG (1998). Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension, 31: 445-450.
50. Torpy DJ, Gordon RD, Lin J-P, Huggard PR, Taymans SE, Stowasser M, Chrousos GP & Stratakis CA (1998). Familial hyperaldosteronism type-II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. Journal of Clinical Endocrinology and Metabolism, 83: 3214-3218.
51. London N, Swales J, Hollinrake K, Bell P & Heagerty A (1992). Familial Conn's syndrome. Postgraduate Medical Journal, 68: 976-977.
52. Greco RG, Carroll JE, Morris DJ, Grekin RJ & Melby JC (1982). Familial hyperaldosteronism, not suppressed oy dexamethasone. Journal of Clinical Endocrinology and Metabolism. 55: 1013-1016.
53. Torpy DJ, Gordon RD & Stratakis CA (1998). Linkage analysis of familial hyperaldosteronism type II - absence of linkage to the gene encoding the angiotensin II receptor type 1. Journal of Clinical Endocrinology and Metabolism, 83: 1046.
54. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M & Gordon RD (1995). A new genetic test for familial hyperaldosteronism type 1 aids in the detection of curable hypertension. Biochemical and Biophysical Research Communications, 207: 565-571.
55. Katoh T, Ise T, Takakuwa H, Yokoyama H & Kobayashi A (1997). A new variant of familial hyperaldosteronism. Proceedings of the 14th International Congress of Nephrology, Washington, DC (Abstract P1813).